Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SanBio Co ( (JP:4592) ) just unveiled an announcement.
SanBio reported another year of losses for the fiscal year ended January 31, 2026, posting an operating loss of ¥3.79 billion and net loss of ¥3.84 billion, while operating revenue remained at zero. Despite the continued red ink, the company’s financial position strengthened sharply, with total assets rising to ¥15.62 billion and net assets to ¥13.60 billion, largely supported by robust financing cash inflows of ¥15.96 billion.
The company forecasts deeper losses in the fiscal year ending January 31, 2027, projecting a full-year net loss of ¥5.64 billion and maintaining a zero-dividend policy as it prioritizes investment over shareholder payouts. Importantly, the forecast excludes any potential revenue from its AKUUGO therapy because pricing has not yet been set, suggesting earnings could improve once pricing is determined and sales begin, but leaving near-term visibility limited for investors.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2054.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., listed on the Tokyo Stock Exchange, operates in the biopharmaceutical industry with a focus likely on regenerative or advanced therapies, as suggested by its product pipeline including AKUUGO. The company remains in a development and investment phase, with no reported operating revenue and a strategy centered on advancing its products toward commercialization rather than generating near-term profit.
Average Trading Volume: 1,356,507
Technical Sentiment Signal: Buy
Current Market Cap: Yen157.6B
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.